Several preclinical studies have examined the expression of PSMA in thyroid tissue, various types of thyroid cancer, lymph node metastases, in vivo small animal models, its potential role as a biomarker for tumor aggressiveness, and its correlation with patients’ RAI positivity or negativity. The gene discussed is FOLH1; the disease is neoplasm.